PMV Pharmaceuticals (PMVP) Common Equity (2019 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly Common Equity came in at $88.0 million in Q1 2026, down 45.06% YoY from $160.1 million in Q1 2025, and down 15.99% on a QoQ basis from $104.7 million in Q4 2025.
PMV Pharmaceuticals (PMVP) Common Equity (2019 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 8 years of Common Equity data on file, last reported at $88.0 million in Q1 2026.
- Quarterly Common Equity fell 45.06% year-over-year to $88.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.0 million (down 45.06% YoY) and the FY2025 annual result came in at $104.7 million, down 40.53% from the prior year.
- Common Equity fell to $88.0 million in Q1 2026, from $104.7 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $291.8 million in Q1 2022 to a low of $88.0 million in Q1 2026.
- A 5-year average of $200.2 million and a median of $214.3 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity declined 1.6% — and 2026, when it sank 45.06%.
- Tracing PMVP's Common Equity over 5 years: stood at $246.0 million in 2022, then decreased by 8.27% to $225.7 million in 2023, then fell by 21.98% to $176.1 million in 2024, then sank by 40.53% to $104.7 million in 2025, then dropped by 15.99% to $88.0 million in 2026.
- The last three Common Equity figures came in at $88.0 million (Q1 2026), $104.7 million (Q4 2025), and $121.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | PMV Pharmaceuticals | 70.74 Mn | -8.69 Mn | - | 71.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 87.97 Mn |
| Dec 31, 2025 | 104.71 Mn |
| Sep 30, 2025 | 121.00 Mn |
| Jun 30, 2025 | 140.61 Mn |
| Mar 31, 2025 | 160.11 Mn |
| Dec 31, 2024 | 176.08 Mn |
| Sep 30, 2024 | 197.91 Mn |
| Jun 30, 2024 | 214.32 Mn |
| Mar 31, 2024 | 212.68 Mn |
| Dec 31, 2023 | 225.69 Mn |
| Sep 30, 2023 | 237.61 Mn |
| Jun 30, 2023 | 217.81 Mn |
| Mar 31, 2023 | 230.17 Mn |
| Dec 31, 2022 | 246.03 Mn |
| Sep 30, 2022 | 261.19 Mn |
| Jun 30, 2022 | 276.97 Mn |
| Mar 31, 2022 | 291.84 Mn |
| Dec 31, 2021 | 308.56 Mn |
| Sep 30, 2021 | 324.95 Mn |
| Jun 30, 2021 | 337.85 Mn |